Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

Weight Loss After Bariatric Surgery

Wegovy: A Breakthrough in Weight Loss?

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

How Oral GLP-1 Drugs Work For Weight Loss

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

The Natural Molecule That Could Rival Ozempic

Vegetarian Diets for Weight Loss

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Circadian Rhythm and Weight Loss

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

Unexplained Weight Loss: When It Might Signal a Health Problem

See more featured articles »

Military Diet: Health Risks

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Does Cinnamon Help with Weight Loss?

Cachexia and Cancer

Mental Health Disorders, Weight Gain, and Exercise

How Does Semaglutide Work to Lose Weight?

Semaglutide and Weight Loss in Menopause

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Cachexia / Wasting Syndrome

Latest Weight Loss News and Research

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

Experimental RNA therapy enhances weight loss while preserving lean muscle

GLP-1 drugs have revolutionized obesity treatment, but they can lead people to lose muscle mass along with fat. And when patients stop treatment, they often regain their weight - primarily as fat.

21 Sep 2026

GLP-1 medications place children at risk for nutritional deficiencies

Children prescribed GLP-1 medications for weight loss, prediabetes, or type 2 diabetes are at risk for nutritional deficiencies – diagnosed in nearly one in six patients (16.8%) within the first year – according to a new study published in the journal Childhood Obesity.

21 Sep 2026

HIV awareness emphasizes prevention, treatment and healthy aging

About 1.2 million people in the United States are living with HIV, or human immunodeficiency virus. Because of major advances in medical treatment and technology, people with HIV are living long, healthy lives.

18 Sep 2026

Social media influencers drive food misinformation across Europe

Scrolling through social media can mean encountering a supplement promising better health, a drink offering quick weight loss or a food promoted as a "superfood".

18 Sep 2026

Time-restricted eating may slow early-stage Huntington's disease

A simple change in when people eat may offer a promising new approach for Huntington's disease, according to research led by Oregon Health & Science University.

17 Sep 2026

Study identifies bile acid that helps reduce excess fat accumulation in the liver

Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common condition that causes excess fat to build up in the liver, affecting about one-quarter of adults worldwide.

17 Sep 2026

Experts call for eating-disorder screening before GLP-1 treatment

An international multidisciplinary panel developed consensus-based recommendations for GLP-1 receptor agonist use in people with eating disorders, calling for screening, individualized monitoring, patient education, and further research into safety and potential therapeutic effects. The experts cautioned that current evidence remains limited and inconsistent, particularly outside binge eating disorder, and identified major gaps in understanding the risk of new or recurrent eating disorders during treatment.

16 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

An 8-hour eating window stood out for weight loss, but the full picture is more complicated

A pooled analysis of individual data from five time-restricted eating trials involving 124 adults linked shorter eating windows with modestly greater weight loss. Eight-hour TRE was associated with greater weight loss than 12-hour TRE and controls, while cardiometabolic outcomes showed no consistent relationship with eating-window duration and several weight associations weakened after adjustment.

14 Sep 2026

Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children

Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that potentially can be reversed with a new class of weight loss drugs used widely by adults

11 Sep 2026

Refined starch activates immune pathways after low-carb weight loss

After substantial weight loss on a very-low-carbohydrate diet, participants who switched to a diet rich in refined starch showed greater activation of circulating immune and metabolic pathways than those who continued the low-carbohydrate diet or consumed a high-carbohydrate diet rich in added sugar. Mouse experiments suggested that activation of the complement immune pathway may help explain the inflammatory response associated with starch intake.

10 Sep 2026

Digital companion apps help secure long-term habits during GLP-1 therapy

Glucagon-like peptide-1 (GLP-1) medications have revolutionized weight management, yet high dropout rates and rapid weight regain remain significant hurdles for many patients.

9 Sep 2026

Non-nutritive sweeteners may aid sugar reduction without affecting weight or health

The review, led by Eva Marija Čad of the University of Ljubljana and Wageningen University & Research, alongside Professor Graham Finlayson of the University of Leeds and colleagues from other institutions in the Netherlands, Denmark, Spain and Belgium, was developed in connection with a 2025 webinar series hosted by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS).

9 Sep 2026

GLP-1 treatment linked to 40% fewer asthma attacks

The diabetes and weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

7 Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

7 Sep 2026

Bariatric surgery restores menstrual cycles and reduces polycystic ovaries in obese women

Metabolic bariatric surgery improves menstrual cycle frequency and symptoms of polycystic ovaries in women living with obesity, a new study from the University of Surrey reports.

7 Sep 2026

Dual-drug microneedle patch targets inflammation and fat browning

The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide currently suffer from obesity, and forecasts warn the number will rise above 4 billion by 2035, accounting for more than half the global population.

4 Sep 2026

Childhood obesity prescriptions for GLP-1 drugs surge in the U.S.

Although the number of US children under age 12 with obesity being prescribed the weight loss drugs Saxenda, Wegovy, and Zepbound remains low, the number is 310 times higher in June 2026 than it was in 2019, when the drugs were initially prescribed, a new study shows.

4 Sep 2026